Design, synthesis and evaluation of benzofuran-acetamide scaffold as potential anticonvulsant agent.

A series of N-(2-(benzoyl/4-chlorobenzoyl)-benzofuran- 3-yl)-2-(substituted)-acetamide derivatives (4a-l, 5a-l) was synthesized in good yield. All synthesized compounds were in agreement with elemental and spectral data. The anticonvulsant activity of all synthesized compounds was assessed against the maximal electroshock induced seizures (MES) model in mice. Neurotoxicity was evaluated using the rotarod method. The majority of compounds exhibited anticonvulsant activity at a dose of 30 mg kg-1 body mass during 0.5-4 h, indicating their ability to prevent seizure spread at low doses. Relative to phenytoin, [N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(cyclohexyl( methyl) amino)-acetamide] (5i) and [N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-methylpiperidin-1- yl)-acetamide] (5c) demonstrated comparable relative anticonvulsant potency of 0.74 and 0.72, respectively, whereas [(N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-(furan-2-carbonyl)-piperazin-1-yl)-acetamide] (5f) exhibited the lowest relative potency of 0.16. The ALD50 of tested compounds ranged from 1.604 to 1.675 mmol kg-1 body mass. The ED50 of synthesized compounds ranged from 0.055 to 0.259 mmol kg-1 (~23.4 to 127.6 mg kg-1) body mass. The pharmacophore mapping of the examined compounds on standard drugs (phenobarbital, phenytoin, ralitolin and carbamazepine) strongly suggests that these compounds may exert their anticonvulsant activity via the same established mechanism as that of known drugs.

Improved efficiency and stability of secnidazole - An ideal delivery system.

Secnidazole (α,2-Dimethyl-5-nitro-1H-imidazole-1-ethanol) is a highly effective drug against a variety of G(+)/G(-) bacteria but with significant side effects because it is being used in very high concentration. In this study, gold nanoparticles (GNPS) were selected as a vehicle to deliver secnidazole drug at the specific site with more accuracy which made the drug highly effective at substantially low concentrations. The as-synthesized GNPs were capped with Human Serum Albumin (HSA) and subsequently bioconjugated with secnidazole because HSA provides the stability and improves the solubility of the bioconjugated drug, secnidazole. The quantification of covalently bioconjugated secnidazole with HSA encapsulated on enzymatically synthesized GNPs was done with RP-HPLC having SPD-20 A UV/VIS detector by using the C-18 column. The bioconjugation of GNPs with secnidazole was confirmed by Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS). The bioconjugated GNPs were characterized by UV-VIS spectroscopy, TEM, Scanning Electron Microscopy (SEM) and DLS. Zeta potential confirmed the stability and uniform distribution of particles in the emulsion of GNPs. The separation of bioconjugated GNPs, unused GNPs and unused drug was done by gel filtration chromatography. The minimal inhibitory concentration of secnidazole-conjugated gold nanoparticles (Au-HSA-Snd) against Klebsiella pneumonia (NCIM No. 2957) and Bacillus cereus (NCIM No. 2156) got improved by 12.2 times and 14.11 times, respectively, in comparison to pure secnidazole. Precisely, the MIC of Au-HSA-Snd against K. pneumonia (NCIM No. 2957) and B. cereus (NCIM No. 2156) were found to be 0.35 and 0.43 µg/ml, respectively whereas MIC of the pure secnidazole drug against the same bacteria were found to be 4.3 and 6.07 µg/ml, respectively.

Effect of carbamazepine on the pharmacokinetic parameters of CDRI-97/78 following coadministration to rats.

Coadministration of 2 or more drugs may result in unexpected toxicity. This study aimed to evaluate the effect of carbamazepine coadministration on the pharmacokinetics of CDRI-97/78, an 1,2,4-trioxane antimalarial agent. Firstly, 97/78 was administered alone and then 97/78 and carbamazepine were coadministered to male and female rats. An revalidated LC-MS/MS method was used for quantitation of 97/63 since 97/78 is instantly and completely converted to 97/63 (an in-vivo active metabolite). The Tmax and Cmax values of 97/63 were 1.75±0.77 h and 862±306 ng/mL in male rats whereas in female rats they were 5.45±0.76 h and 662.75±95.09 ng/mL after a single dose of 97/78 alone. However, following coadministration of 97/78 and carbamazepine, the values for Tmax and Cmax were 1.06±0.16 h and 533±153 ng/mL in male rats and 2.23±1.93 h and 636.5±112.4 ng/mL in female rats. The half life of 97/63 following a single oral dose of 97/78 or coadministration with carbamazepine to male rats was 6.98±0.63 h and 6.64±0.54 h, respectively; the values in female rats were 7.5±0.5 h and 5.48±0.37 h. A statistically insignificant difference (P>0.05) was observed with the student t-test for the pharmacokinetic parameters of 97/63 following oral administration of 97/78 alone or coadministration of 97/78 and carbamazepine except for MRT in female rats. Intersex statistical comparison also showed an insignificant difference for 97/63 following oral administration of 97/78 alone or in combination with carbamazepine except for MRT, which supports coadministration of 97/78 and carbamazepine.

Identification of novel 2-((1-(benzyl(2-hydroxy-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)benzoic acid analogues as BMP-2 stimulators.

The synthesis and SAR studies of 10 new chemical entities (NCEs) that have shown BMP-2 stimulation and osteoblast differentiation are reported. Among these, 2-((1-(benzyl(2-hydroxy-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)benzoic acid (11) was the most effective while its analogue 13 also showed good activity in inducing osteoblast BMP-2 production. Compound 11 induced osteoblast differentiation in vitro, and this effect was abrogated by a physiological BMP-2 inhibitor, noggin. It also exhibited dose dependent increase in nascent bone formation (2.16- and 3.12-fold more than the control at 1 and 5 mg/kg dose, respectively) at the fracture site in rats. At the maximum osteogenic concentration, compound 11 significantly inhibited osteoblastic proteosomal activity. This compound was safe, as it had no effect on BMP synthesis in cardiovascular tissue.

Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats.

Reports regarding drug toxicity and adverse events resulting from coadministration of multiple drugs are increasing at an alarming rate. CDRI-97/78 is an 1,2,4-trioxane antimalarial agent under development which gets metabolized to the in vivo active metabolite 97/63. In order to assess its drug interaction potential, CDRI-97/78 was administered alone and in combination with lamotrigine to male and female rats via the oral route. Quantification of the active metabolite 97/63 in rat plasma was achieved with an LC-MS/MS assay. After oral administration of 97/78, the Tmax and Cmax values of 97/63 in male rats were 1.75±0.77 h and 862±306 ng/mL while female rats showed values for Cmax of 622.75±95.09 ng/mL and for Tmax of 7.5±0.5 h. Coadministration of 97/78 and lamotrigine resulted in decreased Tmax and Cmax values in both male and female rats (Tmax and Cmax of 0.77±0.16 h and 58.58±6.43 ng/mL in male rats; 1.13±0.22 h and 62.95±12.00 ng/mL in female rats, respectively). A statistically significant difference (P<0.05) was observed for the pharmacokinetic parameters of 97/63 after oral administration of 97/78 alone and upon its coadministration with lamotrigine except for the Cmax and Tmax values in male and for the T1/2 value in female rats. Statistically, no significant difference for the pharmacokinetic parameters of 97/63 between male and female rats after oral administration of 97/78 alone or in combination with lamotrigine was determined except for Tmax. The study indicates that coadministration of 97/78, an antimalarial agent, and the antiepileptic lamotrigine may require dose adjustments. Additional clinical drug interaction trials may be required to confirm these findings.

Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients.

The responsiveness of renin-angiotensin and kallikrein-kinin systems to furosemide challenge has been investigated in forty-six diabetic patients (34 NIDDM/12 IDDM), subdivided into Group I (uncomplicated DM), Group II (DM with hypertension), Group III (DM with nephropathy), Group IV (DM with hypertension and nephropathy) and a control group of 10 healthy volunteers. Plasma renin activity (PRA) was estimated by radioimmunoassay in blood samples drawn before and 10 min after furosemide administration (0.5 mg/kg i.v.). Urinary kallikrein levels were measured by bioassay using estrogenized rat uterus preparation in 4h urine samples collected before and after the diuretic. Urinary Na+ and K+ were also measured. The basal PRA in diabetics was not significantly different from controls, whereas, urinary kallikrein levels were markedly low in all patients. Both PRA and kallikrein levels increased after furosemide in controls while in diabetics this response was severely blunted. In a subset of Group I, a paradoxical fall in PRA and kallikrein levels was noted after furosemide, an effect similar to that observed in patients with nephropathy (Group III). This response in absence of clinical and biochemical parameters of nephropathy indicates early derangement of renal hemodynamic mechanisms heralding the onset of nephropathy.

Increased brainstem angiotensin-I levels in chronic 2 KIC hypertensive rats.

A study was undertaken on the role of brainstem renin-angiotensin system in maintenance of hypertension in chronic renovascular hypertensive rats. Hypertension was induced by unilateral renal artery clamping, while the contralateral kidney was left intact (2 KIC). Blood pressure (BP), plasma renin activity (PRA) and brainstem angiotensin (ang-I) levels were measured after 24 days, in hypertensive and sham-operated animals. In separate subgroups of these animals, the effect of intracerebroventricular administration of captopril on the parameters listed was studied. The results showed high ang-I levels in 2 KIC rats as compared to controls (P less than 0.05). Captopril administration (500 micrograms/50 microliters icv) caused a fall in BP and increase in brainstem ang-I levels (P less than 0.01). In control animals, however, captopril produced a rise in BP without any significant change in brainstem ang-I levels. Peripheral plasma renin activity was normal, despite significant sodium retention in 2 KIC rats. The results are suggestive of activation of brainstem renin-angiotensin system (RAS) in chronic 2 KIC hypertension.

Some aspects of pharmacological profile of sodium curcuminate.

Rapid i.v. injection of sodium curcuminate (NaC) produced transient hypotension and bradycardia in anaesthetized dogs and cats which were not blocked by bilateral vagotomy, atropine, mepyramine or propranolol. In open-chest anaesthetized cats, decrease in blood pressure and heart rate was accompanied by simultaneous transient reductions in left ventricular systolic pressure, maximal rate of rise of left ventricular pressure and a concomitant increase in left ventricular end-diastolic pressure. It was concluded that the transient hypotensive effect of NaC is due to its myocardial depressant action. NaC exhibited negative inotropic and chronotropic effect on isolated perfused rabbit heart, an antispasmodic effect on smooth muscle of dog s intestine in vivo and of vas deferens of guinea-pig in vitro but no effect on the rectus abdominis muscle of frog or its response to cholinergic stimulation.

Nature of the beta-adrenoreceptors in the tracheal smooth muscle of the adult pig.

Relaxant responses to isoprenaline (ISO), adrenaline (ADR) and noradrenaline (NA) were investigated on carbachol-contracted, isolated tracheal smooth muscle preparations of the adult pig to determine the nature of the beta-adrenoreceptors present. The order of relaxant potencies of the catecholamines on this preparation was ISO greater than ADR greater than NA. The potency ratio at 37 degrees C was 1:0.06:0.005. This suggests that beta 2-adrenoreceptors predominate in isolated tracheal smooth muscle of the adult pig. Though the order of potency for the above catecholamines did not change, at the lower temperatures of 29 degrees and 33 degrees C, the potency ratios were slightly modified to 1:0.0.98:0.004 and 1:0.07:0.004 respectively. pA2 values on pig tracheal smooth muscle were 8.65 and 9.13 respectively, for the non-selective beta-blockers propranolol and alprenolol, and 5.63, 5.20 and 6.26 respectively, for the beta 1 selective blockers practolol, atenolol and metoprolol and 6.82 for the beta 2 selective beta-blocker, H 35/25. The results suggest the existence and predominance of beta 2-adrenoreceptors in tracheal smooth muscle of the adult pig.

Anti-spasmogenic effect of cyproheptadine on guinea-pig ileum.

Antagonistic activity of cyproheptadine against common spasmogens, like acetylcholine, histamine, serotonin, bradykinin and angiotensin, was studied on isolated guinea-pig ileum. Cyproheptadine produced a reversible antagonism of non-competitive type and was most effective against serotonin. It was less potent against histamine, bradykinin and angiotensin and least potent against acetylcholine.

Effect of beta-adrenergic blockers on isolated coronary arterial strip and tracheal smooth muscle of pig.

Isolated coronary arterial strip and tracheal smooth muscle of pig, containing predominantly beta 1- and beta 2-adrenoceptors respectively, have been used for estimating the comparative potency of nine beta-adrenergic blocking agents. The order of potency of the antagonists on the isolated coronary arterial strip was propranolol greater than alprenolol greater than H 64/52 greater than H 64/55 greater than practolol greater than H 87/07 greater than atenolol greater than metoprolol greater than H 35/25, whilst the order of potency on the pig tracheal smooth muscle was alprenolol greater than propranolol greater than H 35/25 greater than H 87/07 greater than H 64/55 greater than H 64/52 greater than metoprolol greater than practolol greater than atenolol. Propranolol and alprenolol were almost equipotent in both the preparations and hence were nonspecific. Although practolol, metoprolol, H 64/55 and H 87/07 were beta 1-selective, their selectivity ratio was comparatively smaller than that of atenolol and H 64/52. The study indicates that H 64/52 and atenolol are the most specific beta-adrenergic blocking agents on isolated coronary arterial strip of pig and that their beta 1/beta 2-ratios are 126 and 120 respectively. H 64/52 like atenolol may be of therapeutic value in cardiovascular disorders.